Urogen Pharma (NASDAQ:URGN – Free Report) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for shares of Urogen Pharma in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.07) per share for the quarter, up from their prior estimate of ($0.37). HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.83) EPS, Q1 2027 earnings at $0.01 EPS, Q2 2027 earnings at $0.17 EPS and FY2027 earnings at $1.05 EPS.
Urogen Pharma (NASDAQ:URGN – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million.
Urogen Pharma Stock Up 1.7%
Shares of NASDAQ:URGN opened at $47.11 on Monday. The business’s 50 day moving average is $37.24 and its 200 day moving average is $27.57. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $48.19. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -23.79 and a beta of 1.57.
Insider Activity
In other news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider owned 119,763 shares in the company, valued at $4,790,520. This trade represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 25,222 shares of company stock worth $892,661. Company insiders own 4.80% of the company’s stock.
Hedge Funds Weigh In On Urogen Pharma
Several institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC raised its stake in shares of Urogen Pharma by 347.5% in the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after buying an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares during the period. Jane Street Group LLC increased its holdings in Urogen Pharma by 94.3% in the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after acquiring an additional 24,839 shares during the last quarter. Cetera Investment Advisers purchased a new stake in Urogen Pharma in the 2nd quarter worth about $361,000. Finally, JPMorgan Chase & Co. increased its holdings in Urogen Pharma by 5.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock worth $5,348,000 after acquiring an additional 19,405 shares during the last quarter. 91.29% of the stock is owned by institutional investors.
Urogen Pharma Company Profile
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Featured Articles
- Five stocks we like better than Urogen Pharma
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
